Flow cytometry and pharmacokinetics

References

• 1. Rohaan MW, Wilgenhof S, Haanen JBA. Adoptive cellular therapies: the current landscape. Virchows Arch. 474, 449–461 (2019).
  MedlineGoogle Scholar
• 2. Albinger N, Hartmann J, Ullrich E. Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Ther. doi:10.1038/s41434-021-00246-w (2021).
  MedlineGoogle Scholar
• 3. Mfarrej B, Gaude J, Couquiaud J et al. Validation of a flow cytometry-based method to quantify viable lymphocyte subtypes in fresh and cryopreserved hematopoietic cellular products. Cytotherapy 23, 77–87 (2021).
  Medline CASGoogle Scholar
• 4. Golubovskaya V, Wu L. Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy. Cancers 8, 36, 1–12 (2016).
  Google Scholar
• 5. Mueller KT, Maude SL, Porter DL et al. 1. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood 130(21), 2317–2325 (2017).
  Medline CASGoogle Scholar
• 6. Sarikonda G, Pahuja A, Kalfoglou C et al. Monitoring CAR-T cell kinetics in clinical trials by multiparametric flow cytometry: benefits and challenges. Cytometry 100, 72–78 (2021).
  Medline CASGoogle Scholar
• 7. Maude SL, Frey N, Shaw P et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).
  MedlineGoogle Scholar
• 8. Fraietta JA, Lacey SF, Orlando EJ et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563–571 (2018).
  Medline CASGoogle Scholar
• 9. Cohen AD, Garfall AL, Stadtmauer EA et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J. Clin. Invest. 129, 2210–2221 (2019).
  MedlineGoogle Scholar
• 10. Liu C, Ayyar VS, Zheng X et al. Model-based cellular kinetic analysis of chimeric antigen receptor-t cells in humans. Clin. Pharmacol. Ther. 109, 716–727 (2021).
  Medline CASGoogle Scholar
• 11. Arnold M, Fluhler E, Gorovits B. Understanding bioanalysis regulations. In: Regulated Bioanalysis: Fundamentals and Practice. Rocci ML Jr, Lowes S (Eds). AAPS Advances in the Pharmaceutical Sciences Series, Springer International Publishing AG Cham, Switzerland, 26 (2017).
  Google Scholar
• 12. Aijaz A, Vaninov N, Allen A et al. Convergence of cell pharmacology and drug delivery. Stem Cells Transl. Med. 8, 874–879 (2019).
  MedlineGoogle Scholar
• 13. O'Hara DM, Xu Y, Liang Z, Reddy MP, Wu DY, Litwin V. Recommendations for the validation of flow cytometric testing during drug development: II assays. J. Immunol. Methods 363(2), 120–134 (2011).
  MedlineGoogle Scholar
• 14. Selliah N, Eck S, Green C et al. Flow cytometry method validation protocols. Curr. Protoc. Cytom. 87, e53 (2019).
  MedlineGoogle Scholar
• 15. Sarikonda G, Mathieu M, Natalia M et al. Best practices for the development, analytical validation and clinical implementation of flow cytometric methods for chimeric antigen receptor T cell analyses. Cytometry 100, 79–91 (2021).
  MedlineGoogle Scholar
• 16. CLSI. Validation of assays performed by flow cytometry; draft guidance. CLSI Document H62. Clinical and Laboratory Standards Institute, PA, USA (2021).
  Google Scholar
• 17. Litwin V, Marder P. Flow Cytometry in the drug development process. In: Flow Cytometry in Drug Discovery and Development. John Wiley & Sons, Inc, NJ, USA, 69–240 (2011).
  Google Scholar
• 18. McKinnon KM. Flow cytometry: an overview. Curr. Protoc. Immunol. 120, 5.1.1–5.1.11 (2018).
  Google Scholar
• 19. Sommer U, Eck S, Marszalek L et al. High-sensitivity flow cytometric assays: considerations for design control and analytical validation for identification of rare events. Cytometry 100, 42–51 (2021).
  MedlineGoogle Scholar
• 20. Piccoli S, Mehta D, Vitaliti A et al. 2019 White Paper on recent issues in bioanalysis: FDA immunogenicity guidance, gene therapy, critical reagents, biomarkers and flow cytometry validation (Part 3 – recommendations on 2019 FDA immunogenicity guidance, gene therapy bioanalytical challenges, strategies for critical reagent management, biomarker assay validation, flow cytometry validation & CLSI H62). Bioanalysis 11, 2207–2244 (2019).
  CASGoogle Scholar
• 21. Maryamchik E, Gallagher KME, Preffer FI et al. New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry. Cytometry B Clin. Cytom. 98, 299–327 (2020).
  MedlineGoogle Scholar
• 22. Rawstron AC, Böttcher S, Letestu R et al. Improving efficiency and sensitivity: European research initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia 27, 142–149 (2013).
  Medline CASGoogle Scholar
• 23. Jones EA, English A, Sally E et al. Optimization of a flow cytometry-based protocol for detection and phenotypic characterization of multipotent mesenchymal stromal cells from human bone marrow. https://doi.org/doi:10.1002/cyto.b.20118Citations 112 (2006).
  Google Scholar
• 24. de Graaf MT, de Jongste AHC, Kraan J et al. Flow cytometric characterization of cerebrospinal fluid cells. Cytometry Part B 80B, 271–281 (2011).
  Google Scholar
• 25. Ng AA, Lee BT, Teo TS et al. Optimal cellular preservation for high dimensional flow cytometric analysis of multicentre trials. J. Immunol. Methods 385, 79–89 (2012).
  Medline CASGoogle Scholar
• 26. Kakkanaiah VN, Pan F, Bennett P. Evaluation of sample stability for cellular kinetics and pharmacodynamic flow cytometry methods. Bioanalysis 11, 1881–1184 (2019).
  CASGoogle Scholar
• 27. Mahnke YD, Roederer M. Optimizing a multicolor immunophenotyping assay. Clin. Lab. Med. 27, 469–485 (2007).
  MedlineGoogle Scholar
• 28. Mair F, Tyznik A. High-dimensional immunophenotyping with fluorescence-based cytometry: a practical guidebook. Methods Mol. Biol. 2032, 1–29 (2019).
  Medline CASGoogle Scholar